VS Pharmtech Co., Ltd. announced on the 13th that it has selected Pharmaron, a global clinical trial contract organization (CRO), and CRS Cube Co., Ltd., a digital clinical trial solution specialist, as partners for the US FDA phase 2 clinical trial of its radiation sensitizer candidate substance 'VS -101'.
'VS-101' is a drug that maximizes the effect of radiation therapy, and is currently under development with the goal of expanding indications for various types of cancer, including head and neck cancer, breast cancer, and glioblastoma. This US phase 2 clinical trial will be conducted targeting head and neck cancer, and efficient and accurate trial performance is expected by utilizing Pharmaron's global clinical operation expertise and CRS Cube's advanced digital clinical trial solution.
Pharmaron is a global CRO established in 2004, and is a global life science service provider that provides all services required for pharmaceutical development. Based in major bases in the US, UK, and China, 25,000 employees provide integrated services to global pharmaceutical and bio companies.
“By working with Pharmaron, VSPharmtech is efficiently managing time, cost, and quality by conducting everything from non-clinical trials to manufacturing of clinical trial drugs and U.S. clinical trials,” said Lee Du-jin, CEO of Pharmaron Korea. “We will do our best based on Pharmaron’s global network and clinical trial execution experience to produce successful results from this U.S. Phase 2 clinical trial.”
For this clinical trial, CRS Cube provides its integrated solutions, cubeCDMS®, cubeIWRS®, and cubeSAFETY®, for data management, randomization, and drug monitoring. CRS Cube’s solutions are highly evaluated for their ease of use and data reliability, and are currently being used in more than 5,000 clinical trials in over 30 countries around the world.
Kim Ki-don, CEO of CRS Cube, said, “The fact that CRS Cube’s solution is being used in this clinical trial is a case that proves our technological prowess and reliability in global clinical trials,” and added, “We will provide efficient management of clinical trial data and stable services.”
“The collaboration with Pharmalon and CRS Cube is an important opportunity to strengthen the competitiveness of global clinical trials and increase the possibility of success,” said Park Shin-young, CEO of VSPharmtech. “We will do our best to provide patients with innovative treatments through this clinical trial.”
- See more related articles
You must be logged in to post a comment.